CLINICAL TRIAL: PXD101 IN RECURRENT OR REFRACTORY CUTANEOUS AND PERIPHERAL T-CEL
临床试验:PXD101 用于治疗复发性或难治性皮肤和外周 T-CEL
基本信息
- 批准号:7717898
- 负责人:
- 金额:$ 0.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-12-01 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:Antineoplastic AgentsClinical TreatmentClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseCutaneousDiseaseFundingGrantIn complete remissionInstitutionInvestigational DrugsLabelMeasuresMultiple MyelomaNeoplasmsNon-Hodgkin&aposs LymphomaPXD101PatientsPeripheralPhasePhase II Clinical TrialsPrior TherapyProgressive DiseaseRandomizedRateRecurrenceRecurrent diseaseRefractoryRelapseResearchResearch PersonnelResourcesSafetySourceStable DiseaseT-Cell LymphomaTimeUnited States National Institutes of HealthUpper armdesignpartial responseresponse
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
This is an open-label, non-randomized, multicenter, Phase II trial to assess the efficacy and safety of an investigational drug, PXD101, monotherapy in patients who have failed at least one line of prior therapy.
The trial design includes two arms; arm A comprises only patients with recurrent Cutaneous T-cell lymphoma (CTCL), and arm B comprises patients with relapsed or refractory Peripheral T-cell Lymphoma
(PTCL) or other T-cell lymphomas.
PXD101 is a promising antineoplastic agent for the treatment of hematological neoplasias, and is currently being evaluated in a Phase II clinical trial for the treatment of multiple myeloma. Further clinical trials in patients with Non-Hodgkin's lymphomas (NHL) will delineate the optimal use of PXD101 in these disorders.
The primary objective of this trial is to determine the efficacy of PXD101 treatment as measured by response rate (CR=complete response; CRu=CR/unconfirmed; PR=partial response; SD=stable disease;
RD=relapsed disease; or PD=progressive disease) using the response criteria of Cheson et al. (Cheson 1999). The secondary objective of the trial is to examine the time to response, the duration of response, and the safety and survival following PXD101 therapy as a single agent.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RAJ ADVANI其他文献
RAJ ADVANI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RAJ ADVANI', 18)}}的其他基金
SGN-40 (ANTI-HUCD40 MAB) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
SGN-40(抗 HUCD40 MAB)治疗非霍奇金淋巴瘤患者
- 批准号:
7605215 - 财政年份:2007
- 资助金额:
$ 0.35万 - 项目类别:
CLINICAL TRIAL: SGN-40 (ANTI-HUCD40 MAB) IN RELAPSED DIFFUSE LARGE B-CELL LYMPHO
临床试验:SGN-40(抗 HUCD40 MAB)治疗复发性弥漫性大 B 细胞淋巴瘤
- 批准号:
7717926 - 财政年份:2007
- 资助金额:
$ 0.35万 - 项目类别:
TRIAL OF MOTEXAFIN GADOLINIUM (MGD) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
莫替沙芬钆 (MGD) 在非霍奇金淋巴瘤患者中的试验
- 批准号:
7605205 - 财政年份:2007
- 资助金额:
$ 0.35万 - 项目类别:
CLINICAL TRIAL: SGN-40 (ANTI-HUCD40 MAB) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
临床试验:SGN-40(抗 HUCD40 MAB)在非霍奇金淋巴瘤患者中的应用
- 批准号:
7717874 - 财政年份:2007
- 资助金额:
$ 0.35万 - 项目类别:
PXD101 IN PATIENTS WITH RECURRENT OR REFRACTORY CUTANEOUS AND PERIPHERAL T-CELL
PXD101 在复发性或难治性皮肤及外周 T 细胞患者中的应用
- 批准号:
7605249 - 财政年份:2007
- 资助金额:
$ 0.35万 - 项目类别:
TRIAL OF MOTEXAFIN GADOLINIUM (MGD) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
莫替沙芬钆 (MGD) 在非霍奇金淋巴瘤患者中的试验
- 批准号:
7375269 - 财政年份:2005
- 资助金额:
$ 0.35万 - 项目类别:
VELCADE IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA
VELCADE 治疗复发或难治性华氏巨球蛋白血症患者
- 批准号:
7375259 - 财政年份:2005
- 资助金额:
$ 0.35万 - 项目类别:
STUDY OF SGN-40 (ANTI-HUCD40 MAB) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
SGN-40(抗 HUCD40 MAB)在非霍奇金淋巴瘤患者中的研究
- 批准号:
7375287 - 财政年份:2005
- 资助金额:
$ 0.35万 - 项目类别:
VELCADE IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA
VELCADE 治疗复发或难治性华氏巨球蛋白血症患者
- 批准号:
7202112 - 财政年份:2004
- 资助金额:
$ 0.35万 - 项目类别:
TRIAL OF MOTEXAFIN GADOLINIUM (MGD) IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
莫替沙芬钆 (MGD) 在非霍奇金淋巴瘤患者中的试验
- 批准号:
7202123 - 财政年份:2004
- 资助金额:
$ 0.35万 - 项目类别:
相似海外基金
Validation of Filtered Interaction Vertex Imaging for Sub-Millimeter Range Monitoring in Heavy-Ion Therapy with Clinical Treatment Beams
临床治疗光束重离子治疗中亚毫米范围监测的滤波交互顶点成像的验证
- 批准号:
560138-2021 - 财政年份:2022
- 资助金额:
$ 0.35万 - 项目类别:
Postgraduate Scholarships - Doctoral
Validation of Filtered Interaction Vertex Imaging for Sub-Millimeter Range Monitoring in Heavy-Ion Therapy with Clinical Treatment Beams
临床治疗光束重离子治疗中亚毫米范围监测的滤波交互顶点成像的验证
- 批准号:
560138-2021 - 财政年份:2021
- 资助金额:
$ 0.35万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
The Role of Disc Nutrition in the Etiology and Clinical Treatment of Disc Degeneration
椎间盘营养在椎间盘退变的病因学和临床治疗中的作用
- 批准号:
10311070 - 财政年份:2020
- 资助金额:
$ 0.35万 - 项目类别:
The Role of Disc Nutrition in the Etiology and Clinical Treatment of Disc Degeneration
椎间盘营养在椎间盘退变的病因学和临床治疗中的作用
- 批准号:
10531879 - 财政年份:2020
- 资助金额:
$ 0.35万 - 项目类别:
Elucidation of mechanisms of itching mediated by basophils in atopic dermatitis and application to clinical treatment
特应性皮炎嗜碱性粒细胞介导的瘙痒机制的阐明及其在临床治疗中的应用
- 批准号:
20K07081 - 财政年份:2020
- 资助金额:
$ 0.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of the role of CXCL5 for embryo aging for development of the innovative clinical treatment to advanced aging infertility patients
鉴定 CXCL5 在胚胎衰老中的作用,以开发针对晚期衰老不孕症患者的创新临床治疗
- 批准号:
19K21351 - 财政年份:2018
- 资助金额:
$ 0.35万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Using Clinical Treatment Data in a Machine Learning Approach for Sepsis Detection
在机器学习方法中使用临床治疗数据进行脓毒症检测
- 批准号:
10258043 - 财政年份:2018
- 资助金额:
$ 0.35万 - 项目类别:
Examination for a new clinical treatment of Prokineticin 2 factor in colorectal cancer
Prokineticin 2因子治疗结直肠癌的新临床治疗方法的检验
- 批准号:
18K16347 - 财政年份:2018
- 资助金额:
$ 0.35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
An Innovative Clinical Treatment for Primary Care Patients with Depression
针对初级保健抑郁症患者的创新临床治疗
- 批准号:
376675 - 财政年份:2017
- 资助金额:
$ 0.35万 - 项目类别:
Studentship Programs
An Innovative Clinical Treatment for Primary Care Patients with Depression
针对初级保健抑郁症患者的创新临床治疗
- 批准号:
383382 - 财政年份:2017
- 资助金额:
$ 0.35万 - 项目类别:
Studentship Programs














{{item.name}}会员




